Bionovis
Bionovis is a Brazilian pharmaceutical biotech (founded 2012 as a JV of Aché, EMS, Hypera Pharma, and União Química) that develops and manufactures biological and biosimilar medicines at its ANVISA-certified Valinhos facility, supplying SUS, private healthcare, and CMO clients.
- Company typePrivate
- Founded2012
- HeadquartersValinhos, Brazil
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bionovis does
Bionovis is a privately held Brazilian pharmaceutical biotechnology company founded in 2012 as a joint venture of four domestic laboratories — Aché, EMS, Hypera Pharma, and União Química. The company develops and manufactures biological and biosimilar medicines using mammalian cell culture technology at an industrial-scale facility in Valinhos, São Paulo, which houses a pilot plant (bioreactors up to 200 L), a quality control laboratory, and three production lines (one continuous perfusion, two fed-batch using single-use reactors) totaling more than 20,000 L of bioreactor volume and capacity to produce up to 250 kg of protein per year across ten biopharmaceuticals. Its marketed portfolio spans monoclonal antibodies (bevacizumab, trastuzumab, rituximab, pertuzumab, nivolumab, adalimumab, etanercept, golimumab, infliximab), fusion proteins (aflibercept), cytokines (interferon beta-1a), and hematology products (eculizumab, pegfilgrastim), addressing oncology, autoimmune disease, neurology, ophthalmology, and hematology.
The revenue model rests on three pillars: (i) supply of biosimilars to the Brazilian public healthcare system (SUS) under Productive Development Partnerships (PDPs) with the Ministry of Health, technology-transfer-licensed from global originators (Samsung Bioepis, Sandoz, Biocon, Dr. Reddy's, Fresenius Kabi, J&J/Janssen, Merck); (ii) private-market commercialization through commercial partnerships with INTAS and mAbxience; and (iii) contract manufacturing organization (CMO) services at the Valinhos plant. Notable commercial brands include Bevanovis® (bevacizumab, launched 2025) and Pegtima® (pegfilgrastim, launched 2023). The company is ANVISA-certified, claims more than 1 million patients impacted and 19 million vials/syringes delivered cumulatively since founding, and is pursuing in-house pipeline candidates BNV-007 and BNV-008 alongside new 2026 partnerships for pertuzumab and additional biosimilars targeting expansion into Latin America and other regulated markets.
Bionovis firmographics
Firmographics- Name
- Bionovis
- Legal name
- BIONOVIS S/A – COMPANHIA BRASILEIRA DE BIOTECNOLOGIA FARMACÊUTICA
- Website
- https://bionovis.com.br
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Bionovis is a Brazilian pharmaceutical biotech (founded 2012 as a JV of Aché, EMS, Hypera Pharma, and União Química) that develops and manufactures biological and biosimilar medicines at its ANVISA-certified Valinhos facility, supplying SUS, private healthcare, and CMO clients.
- Ownership category
- akta.pro rank
Bionovis industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA)
- akta.pro secondary industry
- Other Recombinant Protein Biosimilars (non-mAb, non-hormone) (HLAIAFAL)
Keywords
Where Bionovis is headquartered
LocationHeadquarters
- HQ city
- Valinhos
- HQ country
- Brazil
- HQ region
- Latin America
Offices1 record
Markets served
Bionovis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales
Revenue model
- Public Healthcare Product Sales (SUS): Bionovis supplies biological and biosimilar medicines to the Brazilian public healthcare system (SUS) through Productive Development Partnerships (PDPs) with the Ministry of Health. Products include infliximab, interferon beta-1a, etanercept, trastuzumab, golimumab, rituximab, adalimumab, bevacizumab, nivolumab, pertuzumab, aflibercept, eculizumab, and pegfilgrastim.
- Private Market Commercialization: Commercial partnerships in the private sector through INTAS and mAbxience for distribution and sale of biopharmaceutical products in the Brazilian private market.
- Contract Manufacturing (CMO Services): Bionovis offers contract manufacturing organization services at its industrial plant in Valinhos, São Paulo, enabling pharmaceutical companies to outsource large-scale manufacturing of biopharmaceuticals or production of clinical batches for scientific trials.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Bionovis product offering
Product offeringCore offering
Bionovis manufactures and commercializes biological and biosimilar medicines using mammalian cell culture technology. Its portfolio includes monoclonal antibodies, fusion proteins, and cytokines developed for cancer, autoimmune, neurological, and hematological conditions, supplied primarily to the Brazilian public healthcare system (SUS), the private market, and contract manufacturing (CMO) clients.
Product overview
Bionovis is a Brazilian pharmaceutical biotechnology company pioneering in the production and commercialization of biological and biosimilar medicines. Founded in 2012 as a joint venture of Aché, EMS, Hypera Pharma, and União Química laboratories, the company operates in research, development, manufacturing, and commercialization of highly complex biopharmaceuticals. Their portfolio includes monoclonal antibodies (bevacizumab/Bevanovis®, trastuzumab, rituximab, pertuzumab, nivolumab, adalimumab, etanercept, golimumab, infliximab), fusion proteins (aflibercept), cytokines (interferon beta-1a), and hematology products (eculizumab, pegfilgrastim/Pegtima®). The company also develops proprietary pipeline candidates (BNV-007, BNV-008) and produces biosimilar versions of reference biologics for the Brazilian public healthcare system (SUS) through technology transfer agreements with global partners including Samsung Bioepis, Sandoz, Dr. Reddy's, and Biocon. Products serve therapeutic areas including oncology, immunology, neurology, ophthalmology, and hematology.
Differentiator
Problem solved
Functional benefit
Brands
- Bevanovis (bevacizumab): Bevanovis is a monoclonal antibody that inhibits VEGF and prevents angiogenesis, indicated for treatment of various types of cancer including cervical cancer, ovarian cancer, lung cancer, colorectal cancer, renal cell carcinoma, and breast cancer.
- Pegtima (pegfilgrastim)
Products and services
- Bevanovis (bevacizumab) Biosimilar of bevacizumab, a monoclonal antibody targeting VEGF used in oncology. Supplied to the Brazilian public healthcare system (SUS) and private market for treatment of colorectal, lung, and other cancers.
Quantifiable outcome
- Impacted over 1 million patients with more than 19 million vials and syringes of biopharmaceuticals
- +2 more outcomes
Companies that use Bionovis
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Bionovis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Bionovis partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core.
- Biocon Biologics LtdcoreBionovis, BahiaFarma, and Biocon signed an MoU at the Ficci India-Brazil Business Forum for developing Pertuzumab, a drug for HER-2 metastatic breast cancer. The agreement also promotes collaboration on rare diseases, oncology, and immunosuppressants for public health. Signed in the presence of Brazilian President Luiz Inacio Lula da Silva and Indian Commerce Minister Piyush Goyal.
- BahiaFarmacoreBahiaFarma, Biocon, and Bionovis signed an MoU for developing Pertuzumab for HER-2 metastatic breast cancer treatment, with collaboration on rare diseases, oncology, and immunosuppressants for public health.
- Samsung BioepiscoreTechnology transfer agreements for etanercept, trastuzumab, aflibercept, bevacizumab, and eculizumab biosimilars for supply through SUS (Brazilian Public Healthcare System).
- Janssen-Cilag (Johnson & Johnson)coreTechnology transfer agreement for infliximab (originator biologic) and golimumab for supply through SUS.
- MerckcoreTechnology transfer agreement for interferon beta-1a biopharmaceutical for supply through SUS.
- SandozcoreTechnology transfer agreement for rituximab biosimilar for supply through SUS.
- Fresenius KabicoreTechnology transfer agreement for adalimumab biosimilar for supply through SUS.
- Dr. Reddy'scoreTechnology transfer agreement for nivolumab biosimilar for supply through SUS.
- Bio-Manguinhos/FIOCRUZcorePartnership with leading Brazilian public laboratory for development and supply of biological medicines through SUS.
- FUNEDcorePartnership with public laboratory for development and supply of biological medicines through SUS.
- INTAScoreCommercial partnership for distribution and sale of biopharmaceuticals in the Brazilian private market.
- mAbxiencecoreCommercial partnership for distribution and sale of biopharmaceuticals in the Brazilian private market.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Bionovis competitors and assessment
Company assessmentRegional players
- Bio-Manguinhos (Fiocruz): Bio-Manguinhos is the Brazilian public laboratory arm of Fiocruz and a strategic partner of Bionovis for biological medicine development and SUS supply. Directly comparable as a domestic Brazilian biopharmaceutical manufacturer operating through PDP arrangements.
- Eurofarma Laboratórios: Eurofarma is a major Brazilian pharmaceutical company with growing biotechnology investments. Comparable as a Brazilian pharma expanding into domestic biologics manufacturing and competing for PDP awards and private market share.
Direct peers
- mAbxience: mAbxience is a Spanish-headquartered biosimilar developer and manufacturer of monoclonal antibodies. Bionovis's private-market distribution partner in Brazil; comparable as an emerging biosimilar manufacturer focused on mAb products for global markets.
- Celltrion: Celltrion is a South Korea-based biosimilar pioneer with approved products across oncology, immunology, and ophthalmology. Directly comparable as a mammalian-cell-based biosimilar manufacturer with strong regulatory and commercial capabilities.
- Samsung Bioepis: Samsung Bioepis is a major biosimilar manufacturer and one of Bionovis's core technology transfer partners (etanercept, trastuzumab, aflibercept, bevacizumab, eculizumab). Directly comparable as a biosimilar-focused biopharma with global development and manufacturing footprint.
- Dr. Reddy's Laboratories: Dr. Reddy's is an Indian multinational with a biosimilars portfolio (nivolumab technology partner to Bionovis). Comparable as an integrated pharma manufacturer with biosimilar development and emerging-markets commercialization capabilities.
- Sandoz: Sandoz is the global biosimilars leader and a Novartis division. Technology transfer partner for rituximab biosimilar at Bionovis; operates large-scale biosimilar manufacturing and commercial infrastructure across multiple therapeutic areas.
- Fresenius Kabi: Fresenius Kabi is a global biopharma player with a growing biosimilars franchise. Technology transfer partner to Bionovis for adalimumab; comparable as an integrated manufacturer developing and commercializing biosimilars globally.
- Biocon Biologics: Biocon Biologics is a leading global biosimilar developer and manufacturer. Partner of Bionovis for pertuzumab development; directly comparable as a vertically integrated biosimilar company serving emerging and regulated markets.
Broad incumbents
- Amgen: Amgen is a global biotechnology incumbent that both originates biologics and produces biosimilars. Comparable as a large-scale biomanufacturer with a portfolio spanning oncology, inflammation, and hematology — directly overlapping therapeutic areas with Bionovis.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Bionovis social profiles
Digital presenceBionovis compliance and trust
Trust signalCompliance2 records
Bionovis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bionovis leadership team
Management profileNumber of profiles
Bionovis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bionovis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bionovis
What does Bionovis do?
Bionovis manufactures and commercializes biological and biosimilar medicines using mammalian cell culture technology. Its portfolio includes monoclonal antibodies, fusion proteins, and cytokines developed for cancer, autoimmune, neurological, and hematological conditions, supplied primarily to the Brazilian public healthcare system (SUS), the private market, and contract manufacturing (CMO) clients.
Is Bionovis a public or private company?
Bionovis is a private company. It is classified as corporate owned and is currently operating.
When was Bionovis founded?
Bionovis was founded in 2012. It employs 101 to 250 people.
Where is Bionovis based?
Bionovis is headquartered in Valinhos, Brazil, in the Latin America region.
How does Bionovis make money?
Three revenue lines are on record. Public Healthcare Product Sales (SUS) is the primary driver. The others are private Market Commercialization and contract Manufacturing (CMO Services).
Who are Bionovis's main competitors?
Regional players on record are Bio-Manguinhos (Fiocruz) and Eurofarma Laboratórios. Direct peers are mAbxience, Celltrion, Samsung Bioepis, Dr. Reddy's Laboratories, Sandoz, Fresenius Kabi and Biocon Biologics. Amgen is listed as a broad incumbent.
Does Bionovis have an API?
No public API is recorded for Bionovis.
What industry is Bionovis in?
Bionovis's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAFAA, Monoclonal Antibody (mAb) Biosimilars, with a secondary code of HLAIAFAL, Other Recombinant Protein Biosimilars (non-mAb, non-hormone). Its NAICS code is 325414 and its SIC code is 2836.